Pharmacotherapy of Parkinson Disease Dementia and Lewy Body Dementia

Abstract

The pharmacotherapy of Parkinson disease dementia and Lewy body dementia with cholinesterase inhibitors and selected psychotropic drugs is relatively new. Review of literature supplemented by expert opinion. Cholinesterase inhibitors can be used by primary care practitioners and specialists, with often clinically meaningful results. Primary care practitioners play an essential role in the diagnosis and management of patients with these conditions.

Impact of 18FDG PET and 11C-PIB PET brain imaging on the diagnosis of Alzheimer’s disease and other dementias in a regional memory clinic in Hong Kong

“…Hence, most DLB patients will benefit from ChEIs, and the extent of symptomatic improvement should be monitored after such therapy. 22 Similarly, FTD may be misdiagnosed as AD. The former can also present initially with memory impairment, as illustrated by our FTD patients.…”

Tratamento da demência: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia

“…Os agonistas dopaminérgicos não são recomendados devido ao risco de agravamento das alucinações. Anticolinérgicos são contraindicados [97][98][99]105,106 .…”

Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

“…Dopamine agonists are not recommended due to the risk of worsening hallucinations. Anticholinergics are contraindicated [97][98][99]105,106 .…”